- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00558909
4 Weeks Treatment of Type II Diabetic Patients With BI 44847
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Selected Oral Doses of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes.
The primary objective of the current study is to investigate the safety and tolerability of BI 44847 in male and female patients with type 2 diabetes following oral administration of repeated doses of 100 mg b.i.d, 400 mg b.i.d. and 800 mg b.i.d. over 28 days.
A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 44847 after multiple dosing, including assessment of steady state.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- 1224.4.49002 Boehringer Ingelheim Investigational Site
-
Mainz, Germany
- 1224.4.49003 Boehringer Ingelheim Investigational Site
-
Neuss, Germany
- 1224.4.49001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Zuidlaren, Netherlands
- 1224.4.31001 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and postmenopausal or hysterectomised female patients with proven diagnosis of type 2 diabetes mellitus treated with diet and exercise only or with one or 2 oral hypoglycaemic agent other than glitazones. In case of 2 oral hypoglycaemic agents, at least one of these may be taken at no more than 50% of its maximum dose;
- Age = > 21 and Age = <70 years (female hysterectomised and male patients);
- Age = >55 and Age = <70 years (female postmenopausal patients);
- BMI = >18.5 and BMI = <40 kg/m2 (Body Mass Index);
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
Exclusion Criteria:
- Treatment with insulin, glitazones, or more than one oral hypoglycaemic agent (except if 2 agents and at least one of them not taken at more than 50% of maximum dose);
- Fasted blood glucose > 240 mg/dl on two consecutive days during wash-out; HbA1c > 8.5 % at screening;
- Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia and medically treated hypertension;
- History of relevant allergy/hypersensitivity;
- Marked baseline prolongation of QT/QTc interval;
- History of additional risk factors for TdP;
- Any laboratory value outside the reference range and the clinical relevance is not acceptable in the opinion of the investigator, or the value is more than 3 times higher than the upper limit of the reference range;
- Concomitant medication except for acetylsalicylic acid, statins, antihypertensives (diuretics not allowed), beta-blockers for BPH and occasional use of paracetamol (doses of no more than 1000 mg; no more than 2000 mg per day; no more than 2 days per week);
- Change of drug dosing of allowed co-medication < the last 6 weeks; Intake of any medication < 5 half-lives of the respective drug prior to first administration of study medication or during the trial, except allowed co-medication;
- Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval (based on the knowledge at the time of patient inclusion) < 10 days prior to first administration of study medication or during the trial;
- Use of grapefruit (or its juice) < 10 days prior to first administration of study medication or during the trial;
- Participation in another trial with an investigational drug < two months prior to first administration of study medication or during the trial; Smoker;
- Inability to refrain from smoking on specified trial days; Alcohol abuse;
- Drug abuse;
- Blood donation;
- Excessive physical activity;
- Male patients not using adequate contraception;
- Women of childbearing potential, positive pregnancy test or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Weight and waist circumference - change from baseline
Time Frame: Day 28 (Hour = 647:30)
|
Day 28 (Hour = 647:30)
|
Frequency of patients with maximal increase from baseline QTcF and QTcB interval
Time Frame: 4 weeks
|
4 weeks
|
Frequency of patients with possible clinically significant abnormalities
Time Frame: 4 weeks
|
4 weeks
|
Micturition total frequency - change from baseline
Time Frame: Day 28
|
Day 28
|
Global tolerability - number of patients by category
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (maximum concentration of the analyte in plasma)
Time Frame: Day 1
|
Day 1
|
Tmax (time from dosing to maximum concentration)
Time Frame: Day 1
|
Day 1
|
t1/2 (terminal half-life of the analyte in plasma)
Time Frame: Day 1
|
Day 1
|
λz (terminal rate constant in plasma)
Time Frame: Day 1
|
Day 1
|
C12,1 (concentration of analyte in plasma at 12 hours post-drug administration after administration of the first dose)
Time Frame: Day 1
|
Day 1
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point within the first dosing interval)
Time Frame: Day 1
|
Day 1
|
AUC0-12 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 12 h after administration of the first dose)
Time Frame: Day 1
|
Day 1
|
Ae0-12 (amount of analyte that is eliminated in urine over the time interval 0 h to 12 h)
Time Frame: Day 1
|
Day 1
|
fe0-12 (fraction of analyte excreted unchanged in urine from time points 0 h to 12 h)
Time Frame: Day 1
|
Day 1
|
CLR (renal clearance of the analyte in plasma after extravascular administration - based on 0 - 12 hour data)
Time Frame: Day 1
|
Day 1
|
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Time Frame: Day 1
|
Day 1
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time Frame: Day 1
|
Day 1
|
Cmax,ss (maximum concentration of the analyte in plasma at steady state over a uniform dosing interval)
Time Frame: Day 28
|
Day 28
|
Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)
Time Frame: Day 28
|
Day 28
|
Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)
Time Frame: Day 28
|
Day 28
|
Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the last dose)
Time Frame: Day 28
|
Day 28
|
C12,ss (concentration of analyte in plasma at 12 hours post-drug administration at steady state)
Time Frame: Day 28
|
Day 28
|
tmax,ss (time from dosing to maximum concentration at steady state)
Time Frame: Day 28
|
Day 28
|
tmin,ss (time from dosing to minimum concentration during a dosing interval)
Time Frame: Day 28
|
Day 28
|
AUC0-tz,ss (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point within the last dosing interval)
Time Frame: Day 28
|
Day 28
|
AUC0-12,ss (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 12 h at steady-state)
Time Frame: Day 28
|
Day 28
|
MRTpo,ss (mean residence time of the analyte in the body after 56 administrations (b.i.d.) at steady state)
Time Frame: Day 28
|
Day 28
|
CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)
Time Frame: Day 28
|
Day 28
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state)
Time Frame: Day 28
|
Day 28
|
Ae0-12,ss (amount of analyte that is eliminated in urine at steady state over the time interval 0 to 12 h)
Time Frame: Day 28
|
Day 28
|
fe0-12,ss (fraction of analyte excreted unchanged in urine at steady state over the time interval 0 to 12 h)
Time Frame: Day 28
|
Day 28
|
CLR,ss (renal clearance of the analyte at steady state - based on 0 - 12 hour data)
Time Frame: Day 28
|
Day 28
|
RA,Cmax based on Cmax
Time Frame: following 55 doses (bid)
|
following 55 doses (bid)
|
RA,AUC based on AUCτ
Time Frame: following 55 doses (bid)
|
following 55 doses (bid)
|
Predose concentrations of the analyte in plasma
Time Frame: 5 minutes before drug administration on days 2,3,4,7,14,21,26,27,28 and 29
|
5 minutes before drug administration on days 2,3,4,7,14,21,26,27,28 and 29
|
Change from baseline in UGE, AE0-24
Time Frame: Day 27
|
Day 27
|
Change from baseline in weighted MDG, AUEC0-24
Time Frame: Day 27
|
Day 27
|
Epre-corrected AUEC0-5 following OGTT
Time Frame: Day 28
|
Day 28
|
Cavg (average concentration)
Time Frame: day 28
|
day 28
|
PTF (peak trough fluctuation).
Time Frame: day 28
|
day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1224.4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on BI 44847
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimNot yet recruiting
-
Boehringer IngelheimRecruitingMelanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)Netherlands
-
Boehringer IngelheimCompletedNeoplasms | Carcinoma, Non-Small-Cell LungUnited States, Spain, United Kingdom, Canada, Poland